Paradigm Biopharmaceuticals Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PBIGF research report →
About the company
Melbourne, Australia-based Paradigm Biopharmaceuticals Limited operates as a drug repurposing company, focusing on the discovery and development of therapeutic products for human application. The company's core offering is an injectable formulation of pentosan polysulfate sodium (PPS), which is being developed to address various medical conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, Chikungunya virus, and acute respiratory distress syndrome. The company was established in 2014.
- CEO
- Paul John Rennie
- IPO
- 2019
- Employees
- 8
- HQ
- Melbourne, VIC, AU
Price Chart
- Market Cap
- $65.01M
- P/E
- -1.96
- P/S
- 1252.15
- P/B
- 12.07
- EV/EBITDA
- -1.53
- Div Yield
- 0.00%
- Gross Margin
- -161.09%
- Op Margin
- -63782.77%
- Net Margin
- -59585.74%
- ROE
- -265.55%
- ROIC
- -492.97%
- Revenue
- $52.12K · -20.79%
- Net Income
- $-18,770,745 · 68.00%
- EPS
- $-0.06 · 70.15%
- Op Income
- $-22,886,205
- FCF YoY
- 75.75%
- 52W High
- $0.35
- 52W Low
- $0.10
- 50D MA
- $0.13
- 200D MA
- $0.20
- Beta
- -0.02
- Avg Volume
- 13.36K
Get TickerSpark's AI analysis on PBIGF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PBIGF coverage
Recent articles, reports, and earnings notes.
No research on PBIGF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PBIGF report →Similar companies
Peers in the same neighborhood.